154 related articles for article (PubMed ID: 35880450)
1. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
Goldsmith SR; Liu L; Shiah K
Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
[TBL] [Abstract][Full Text] [Related]
2. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
[TBL] [Abstract][Full Text] [Related]
3. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin Lymphoma --Review].
Tang XY; Wang Y; Xu RR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
[TBL] [Abstract][Full Text] [Related]
4. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
5. Selinexor for the treatment of multiple myeloma.
Podar K; Shah J; Chari A; Richardson PG; Jagannath S
Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
[No Abstract] [Full Text] [Related]
6. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
10. Selinexor: First Global Approval.
Syed YY
Drugs; 2019 Sep; 79(13):1485-1494. PubMed ID: 31429063
[TBL] [Abstract][Full Text] [Related]
11. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
13. Selinexor for the treatment of patients with previously treated multiple myeloma.
Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P
Expert Rev Hematol; 2021 Aug; 14(8):697-706. PubMed ID: 33985401
[TBL] [Abstract][Full Text] [Related]
14. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Kasamon YL; Price LSL; Okusanya OO; Richardson NC; Li RJ; Ma L; Wu YT; Theoret M; Pazdur R; Gormley NJ
Oncologist; 2021 Oct; 26(10):879-886. PubMed ID: 34132444
[TBL] [Abstract][Full Text] [Related]
16. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
Sylvain C
Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
[TBL] [Abstract][Full Text] [Related]
17. The 'comeback' of Selinexor: From toxic to tolerable.
Hashmi H; Green K
Curr Probl Cancer; 2022 Feb; 46(1):100789. PubMed ID: 34479762
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
20. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
